MiniMed™ 780G insulin pump systemLive life with more
Time in Range1,
A hybrid closed loop system for people with Type 1 Diabetes
MiniMed™ 780G system
More Time in Range1, , day and night.
The MiniMed™ 780G system
Could an automated insulin pump system be right for you?
Trial the MiniMed™ 780G system if you are eligible.
Do you have type 1 diabetes and a HbA1c above 58 mmol/mol (7.5%)?
Are you currently using Multiple Daily Injections (MDI) or a different insulin pump?
We will work with your healthcare professional to assess your eligibility using the NICE (National Institute for Health and Care Excellence) criteria for Hybrid Closed Loop systems.
Complete the form at the bottom of this page and we’ll be in touch shortly.
A closer look at the MiniMed™ 780G system
Advanced algorithm
The algorithm adapts to you providing better time in range than other
Wear what you want
Feel free to hide or show the pump depending on your outfit choice.
No daily charging
Unlike other pumps, the 780G doesn't need daily charging.
Freedom to disconnect
Disconnect for up to an hour for activities.
Waterproof design
A tough, easy-to-use pump.
Trusted across Europe
Used by hundreds of thousands, 780G is Europe’s most popular automated insulin pump.
- Choudhary P, et al. Diabetes Technol Ther 2024; 26 (Suppl. 3): S32-S37.
- De Meulemeester J. The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study. Diabetologia. 2024;67(8):1527-1535. doi:10.1007/s00125-024-06171-y
- Petrovski G, et al. Diabetes Care 2023;46(3):544–550
- Di Molfetta S, Di Gioia L, Caruso I, et al. Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Metab Res Rev. 2024;40(6):e3842. doi:10.1002/dmrr.3842
- dQ&A Diabetes Technology Report, 2024 (n= 2,721)
- Fusselman H, et al. FUSS2015D-P - The Extended Wear Infusion Set - A Design for Plastic Waste Reduction. Virtual Diabetes Technology Meeting. 2020
- Arrieta A, et al. Diabetes Obes Metab. 2022;24(7):1370-1379. Mean 80% TIR is reached using the recommended optimal settings of 2 hours active insulin time and 100 mg/dL (5.5 mmol/L) as glucose target for at least 90% of the time.
- Medtronic data on file: MiniMed™ 780G users survey conducted in April-May 2021 in UK, Sweden, Italy, Netherlands and Belgium. Sample size = 789.
- * Compared to MDI + isCGM
- ** Refer to System User Guide - SmartGuard™ feature. Some user interaction required
- ^ A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
- ^^ Multiple Daily Injections (3 bolus and 1 basal insulin per day) requires 28 injections per week vs. 1 with Medtronic Extended Infusion Set.
- # Based on RWE publications.
- ## Terms and Conditions apply. We will work with your healthcare professional to assess your eligibility using the NICE (National Institute for Health and Care Excellence) criteria for Hybrid Closed Loop systems.
- ~ The patients testimonials relates an account of an
individual´s response to the treatment. The account is genuine, typical and documented. However, theindividual´s response does not provide any indication, guide, warranty or guarantee as to the response other patients may have to the treatment. The response other patients have to the treatment could be different. Responses to the treatment discussed can and do vary and specific to the individual patient. - ¥ Refer to Accu-Chek® Guide Link User's Manual
- 1.Choudhary P, et al. Diabetes Technol Ther 2024; 26 (Suppl. 3): S32-S37.
- 2.De Meulemeester J. The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study. Diabetologia. 2024;67(8):1527-1535. doi:10.1007/s00125-024-06171-y
- 3.Petrovski G, et al. Diabetes Care 2023;46(3):544–550
- 4.Di Molfetta S, Di Gioia L, Caruso I, et al. Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Metab Res Rev. 2024;40(6):e3842. doi:10.1002/dmrr.3842
- 5.dQ&A Diabetes Technology Report, 2024 (n= 2,721)
- 6.Fusselman H, et al. FUSS2015D-P - The Extended Wear Infusion Set - A Design for Plastic Waste Reduction. Virtual Diabetes Technology Meeting. 2020
- 7.Arrieta A, et al. Diabetes Obes Metab. 2022;24(7):1370-1379. Mean 80% TIR is reached using the recommended optimal settings of 2 hours active insulin time and 100 mg/dL (5.5 mmol/L) as glucose target for at least 90% of the time.
- 1.Choudhary P, et al. Diabetes Technol Ther 2024; 26 (Suppl. 3): S32-S37.
- 2.De Meulemeester J. The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study. Diabetologia. 2024;67(8):1527-1535. doi:10.1007/s00125-024-06171-y
- 3.Petrovski G, et al. Diabetes Care 2023;46(3):544–550
- * Compared to MDI + isCGM
- ** Refer to System User Guide - SmartGuard™ feature. Some user interaction required
- ^ A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
- ^^ Multiple Daily Injections (3 bolus and 1 basal insulin per day) requires 28 injections per week vs. 1 with Medtronic Extended Infusion Set.
- # Based on RWE publications.
- ~ The patients testimonials relates an account of an individual's response to the treatment. The account is genuine, typical and documented. However, the individual's response does not provide any indication, guide, warranty or guarantee as to the response other patients may have to the treatment. The response other patients have to the treatment could be different. Responses to the treatment discussed can and do vary and specific to the individual patient.
- ¥ Refer to Accu-Chek® Guide Link User's Manual
- ** Refer to System User Guide - SmartGuard™ feature. Some user interaction required
- ^ A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
All clinical data and surveys results included in this document refer to MiniMed™ 780G system used in combination with Guardian™ sensor 3. Information contained herein is not medical advice and should not be used as an alternative to speaking with your doctor. Discuss indications, contraindications, warnings, precautions, potential adverse events and any further information with your health care professional.